SCHEMBL3761284

SCHEMBL3761284

Cc1nc2ccccc2c(=O)n1NC(=O)CC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ GAA P10253 3/20 0.56
▸ ALDH1A1 P00352 2/20 0.55
▸ USP2 O75604 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ KMT2A Q03164 4/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.53
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3791796 0.94 HTT (0.53) HTTSMN1; SMN2GAAALDH1A1USP2
SCHEMBL3760532 0.88 ALDH1A1 (0.57) HTTGAAALDH1A1USP2TSHR
SCHEMBL3765565 0.87 P2RX7 (0.48) HTTSMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL3762001 0.87 KMT2A (0.50) SMN1; SMN2GAAALDH1A1USP2TSHR
SCHEMBL3754201 0.85 P2RX7 (0.46) HTTSMN1; SMN2GAAALDH1A1USP2
SCHEMBL3757585 0.85 P2RX7 (0.47) HTTSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL3785778 0.83 KMT2A (0.53) HTTGAAALDH1A1USP2TSHR
SCHEMBL3761389 0.83 GLA (0.44) HTTSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL3755688 0.83 KMT2A (0.47) SMN1; SMN2GAAALDH1A1KMT2AMEN1
SCHEMBL3785819 0.82 P2RX7 (0.44) HTTSMN1; SMN2ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962639-B2 Potassium channel modulators ABBVIE INC. (US) 2015-02-24 — — US claimed
WO-2010138828-A2 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — WO claimed
US-20100305109-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — US claimed
US-8962639-B2 Potassium channel modulators ABBVIE INC. (US) 2015-02-24 — — US disclosed
WO-2010138828-A2 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — WO disclosed
US-20100305109-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305109-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 HTT 2117/4885SMN1; SMN2 1516/4885GAA 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback